Bone Biologics Corporation (BBLG) has a negative trailing P/E of -0.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -213.41%.
Criteria proven by this page:
Overall SharesGrow Score: 46/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -0.1 | 0.00 | -0.41 | 0.00 | - |
| 2017 | -0.5 | 0.01 | -0.43 | 0.00 | - |
| 2018 | -1.0 | 0.02 | -0.54 | 0.00 | - |
| 2019 | -49.4 | 0.50 | -14.25 | 0.00 | - |
| 2020 | -92.7 | 1.98 | -12.35 | 0.00 | - |
| 2021 | -67.7 | -14.47 | 16.59 | 0.00 | - |
| 2022 | -4.8 | 0.29 | 1.21 | 0.00 | - |
| 2023 | -0.8 | -0.09 | 2.46 | 0.00 | - |
| 2024 | -2.1 | 0.02 | 2.46 | 0.00 | 37.55% |
| 2025 | -0.5 | 0.01 | 0.32 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $0.00 | $0.00 | $-25.88M | - |
| 2017 | $0.00 | $0.00 | $-7.05M | - |
| 2018 | $0.00 | $0.00 | $-4.43M | - |
| 2019 | $-66.97 | $0.00 | $-3.42M | - |
| 2020 | $-151.20 | $0.00 | $-1.83M | - |
| 2021 | $-84.00 | $0.00 | $-1.61M | - |
| 2022 | $-31.20 | $0.00 | $-1.49M | - |
| 2023 | $-34.01 | $0.00 | $-8.95M | - |
| 2024 | $-4.83 | $0.00 | $-4.11M | - |
| 2025 | $-2.65 | $0.00 | $-3.11M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.93 | $-1.93 – $-1.93 | $0.00 | $0.00 – $0.00 | 1 |
| 2027 | $-1.62 | $-1.62 – $-1.62 | $0.00 | $0.00 – $0.00 | 1 |
